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Abstract: The brain is vulnerable to excessive oxidative insults because of its abundant lipid content,
high energy requirements, and weak antioxidant capacity. Reactive oxygen species (ROS) increase
susceptibility to neuronal damage and functional deficits, via oxidative changes in the brain in
neurodegenerative diseases. Overabundance and abnormal levels of ROS and/or overload of metals
are regulated by cellular defense mechanisms, intracellular signaling, and physiological functions of
antioxidants in the brain. Single and/or complex antioxidant compounds targeting oxidative stress,
redox metals, and neuronal cell death have been evaluated in multiple preclinical and clinical trials as a
complementary therapeutic strategy for combating oxidative stress associated with neurodegenerative
diseases. Herein, we present a general analysis and overview of various antioxidants and suggest
potential courses of antioxidant treatments for the neuroprotection of the brain from oxidative
injury. This review focuses on enzymatic and non-enzymatic antioxidant mechanisms in the brain
and examines the relative advantages and methodological concerns when assessing antioxidant
compounds for the treatment of neurodegenerative disorders.
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1. Introduction
Oxidative stress is considered as a detrimental condition for normal brain functioning. Since the
brain uses chemically diverse reactive species for signal transmission, it is susceptible to oxidative
stress [1]. The human brain consists of more than 86 billion neurons and over 250–300 billion glial
+cells, which consume over 20% of the total basal oxygen [2,3]. The mitochondria in the brain use the
inspired basal oxygen to reduce O2 to H2O to support adenosine triphosphate (ATP) synthesis [4].
The electron transport chain in the mitochondria is not efficient and leakage of reactive oxygen species
(ROS) from the mitochondria occurs when there is excess of oxygen [5]. Redox signaling in the brain
functions as an intrinsic sensor to oxidative stress, when signals go awry during pathological conditions.
Brain tissue has a high rate of oxidative metabolic activity, intense production of reactive oxygen
metabolites, relatively low levels of antioxidants, low repair capacity, non-replicating neuronal cells,
and a high membrane surface to cytoplasm ratio [6]. The cellular antioxidant system that prevents
tissue damage is composed of endogenous and exogenous antioxidants that have the ability to reduce
different chemicals. In biological antioxidant defense systems, both endogenous and exogenous
antioxidants are classified into enzymatic antioxidants and non-enzymatic antioxidants, including
oxidative enzyme inhibitors, antioxidant enzyme cofactors, ROS/RNS scavengers, and transition
metal chelators [7,8]. These two main antioxidant systems play an important role in maintaining the
balance between pro-oxidant and antioxidant agents in the brain and in mitigating oxidative stress [9].
The present review focuses on enzymatic and non-enzymatic antioxidant mechanisms in the brain
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and examines the relative advantages of antioxidant compounds for the treatment of various brain
diseases. Therefore, this review will describe selective antioxidants shown to have neuroprotective
effects that limit neurodegenerative disease.
2. Factors That Contribute to Vulnerability of the Brain to Oxidative Stress
Free radicals or other reactive molecules disturb cellular energy metabolism and cause oxidative
stress. Endogenous redox imbalance by pro-oxidant and antioxidant agents occurs as a result of free
radicals, which play an important role in oxidative stress, cell death, and tissue damage. Increased free
radical production due to excess pro-oxidant mechanisms can react with lipids, proteins, nucleic
acids, and other biomolecules which can alter their structure and function. A high concentration
of polyunsaturated fatty acids exists in membrane lipids in the brain [10]. These are sources of
decomposition reaction in the form of lipid peroxidation, in which a single initiating free radical
can precipitate the destruction of adjacent molecules. Polyunsaturated fatty acids especially serve
as major biological targets for oxidative damage induced by ROS. Other candidate molecules that
serve as biological targets of free radicals are nucleic acids. Breaks in DNA or modified bases can
result in aberrant gene expression and cell death [11]. Moreover, free radicals can also oxidize
the backbone and side chains of proteins, thereby disrupting the function of enzymes, receptors,
neurotransmitters, and structural proteins by oxidative modification [12]. Highly reactive oxygen
radicals are produced in the brain as a result of interactions between various transition metals and their
reducing equivalents. Transition metals including iron, copper, zinc, and manganese, are associated
with increased free radical production by the Fenton reaction [13,14]. Since the brain has abundant
lipid content, high energy requirements, and weak antioxidant capacity, it is an easy target for excessive
oxidative insults. Specifically, ROS increase susceptibility to neuronal damage and functional decline
via brain oxidation in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis
(ALS), cerebrovascular disorders, psychiatric disorders, and other neurodegenerative diseases [6,13,15]
(Figure 1).
Considering a detailed perspective on signaling, the rationale underlying the vulnerability of the
neurons in the brain to oxidative stress are as follows: In redox signaling, O2−/H2O2 generation by
the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 induces the
activation of signaling proteins via sulfenic acid formation [16,17]. The brain is dependent on Ca2+
signaling for synaptic plasticity, a fundamental brain function, and it expends considerable amounts of
ATP to maintain intracellular Ca2+ homeostasis. Synaptic terminal glutamate-induced Ca2+ transients
activate neuronal nitric oxide synthase (nNOS)-mediated NO· generation, and additionally, Ca2+
overloaded in the mitochondria induces O2−/H2O2 generation which can lead to ONOO· production
and excitotoxicity [18–20]. Particularly, the mitochondria generate O2− in complex I and complex III
and the monoamine oxidase enzyme isoform catalyzes H2O2 generation during metabolism [21–23].
The human brain consumes over 25% circulating glucose to support neuronal function; however, protein
inactivation by the formation of advanced end glycation products (AGE) due to decreased glycolytic
rates can cause glucose-induced oxidative stress [24,25]. Neurotransmitters with a catechol group
render the brain sensitive to oxidative stress. Redox-active transition metals catalyze the auto-oxidation
of dopamine to a semiquinone radical during neurotransmitter oxidation [26–28]. The mature neurons
of the brain have abundant and multiple mechanisms that promote long-term neuronal survival and
prevent cell death; however, the brain has a comparatively weak endogenous antioxidant defense
system relative to other tissues and is susceptible to imbalance in redox homeostasis. For instance,
neurons with 50 times lower catalase content than hepatocytes have constrained glutathione peroxidase
4 (GPX4) activity (owing to low glutathione [GSH] content) and a modest antioxidant defense
mechanism [29–31]. Microglia monitor neuronal activity for removal of unhealthy cells, neuronal
wiring during development, and activity dependent synaptic plasticity. They generate O2− via NADPH
oxidase 2 (NOX2) within an end-foot process, thus influencing brain oxidation [32,33]. Redox-active
transition metals, such as Fe2+ and Cu+, are enriched in the brain and therefore contribute to ferroptosis
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by catalyzing peroxyl (ROO·) and alkoxyl (RO·) radical generation [34,35]. Lipid peroxidation,
which involves initiation, oxygenation, propagation, and termination, occurs within the neuronal cell
membrane [36]. The brain uses nNOS and NOX isoforms to maintain essential functions. However,
nNOS/NOX expression is associated with NO· generation, which can be spatially co-generated
while producing ONOO· [37,38]. In summary, these interconnected, myriad factors render the brain
vulnerable to oxidative stress. Furthermore, excessive production of reactive species and insufficient
activity of antioxidant defense systems have been implicated in the pathogenesis of neurodegeneration.
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Figure 1. Development of various diseases by the pathophysiology of oxidative stress in the brain.
Balance and imbalance between pro-oxidants and antioxidants against reactive oxygen species
production induce oxidative stress and are consequently involved in neuronal damage resulting
in the neurodegenerative diseases.
3. Role of Antioxidants in the Brain
Antioxidants act in two ways: First, the antioxidant defense systems, which are initiated against
oxidative damage, prevent generation of ROS, and block and capture the generated radicals [39].
These systems are present in the aqueous and membrane compartments of cells; they can be enzymatic
or non-enzym ic. The first line of defense has been ide tified as an nzymatic antioxida t system that
inclu s superoxide dismutase, atalase, and glutathione pero se. The second line of defense is
represented by reduced thiol and non-enzymatic antioxidants, including hydro- and lipo-soluble or
metabolic compounds [7]. Second, during the antioxidant repair process, the removal of damaged
biomolecules before their aggregation causes alterations in cell metabolism. The intervention by the
repair systems consists of repairing oxidatively damaged nucleic acids by specific enzymes, removing
oxidized proteins by the proteolytic systems, and repairing oxidized lipids by phospholipases,
peroxidases, or acryl transferases [8,39,40].
Antioxidants act to directly scavenge oxidizing radicals and regenerate oxidized biomolecules
in organisms. Neuronal cells possess several factors that minimize oxidative damage and a complex
Int. J. Mol. Sci. 2020, 21, 7152 4 of 29
antioxidant system consisting of various antioxidant enzymes and non-enzymes. With regard to
the mechanism of action of antioxidants, antioxidants respond to different steps of oxidative radical
processing and can be considered by taking into account the different steps of lipid peroxidation in cell
membranes such as: initiation, propagation, and chain termination [36]. The first step of initiation of
lipid peroxidation can be promoted by diverse exogenous factors, endogenous enzyme systems, and the
electron transport chain in the mitochondria. The propagation step of peroxidation is initiated by the
addition of oxygen to carbon-centered radicals, which are generated at, or near, the diffusion-controlled
rate. Propagation is represented by the transfer of a hydrogen atom to the chain carrying peroxyl
radicals and occurs at a relatively slow rate. Antioxidants can inhibit lipid peroxidation by removing
molecular oxygen or by decreasing the local concentration of molecular oxygen, removing pro-oxidative
metal ions, trapping aggressive ROS, scavenging chain initiating radicals, breaking the chain of free
radical reactions, and quenching singlet oxygen [7,41]. In its protective role, enzymatic antioxidants
are chain-breaking antioxidants which are able to scavenge radical species while non-enzymatic
antioxidants are singlet oxygen quenchers, metal chelators, oxidative enzyme inhibitors, peroxide
decomposers, and/or ultra violet (UV) radiation absorbers [7]. Additionally, antioxidant enzymes can
catalyze the synthesis or regeneration of non-enzymatic antioxidants.
3.1. Enzymatic Antioxidants
3.1.1. Superoxide Dismutase
Superoxide dismutase (SOD), which belongs to the enzymatic defense system, changes the
superoxide radical anion to H2O2 by oxidative decay. Another function of SOD is to protect dehydratase
from free radical superoxide inactivation. There are three forms of SOD in humans. SOD-1, a copper-zinc
containing SOD (Cu, Zn-SOD), is present in the cytosol and specifically catalyzes dismutation in
a pH-independent medium [42]. SOD-1 protein is a homodimer composed of eight antiparallel
beta strands and two metal atoms that catalyze the conversion of toxic O2− anions to H2O2 and O2.
Specifically, copper minerals play a crucial role in the catalytic function of this enzyme, while zinc
is important for structural integrity [43]. SOD-1 plays an important role as a first line of defense
by detoxifying superoxide radicals. In addition, the lack of this enzyme exhibited a pronounced
susceptibility to paraquat toxicity. SOD-2, a manganese containing SOD (Mn-SOD), is found in the
mitochondrial matrix and reduces the superoxide radical anion generated in the electron transport
chain [44]. A detailed analysis revealed that the SOD-2 subunit needs one metal atom and that it is
functionally disabled in the absence of Mn atoms in the active site. SOD-2 attracts O2− and turns
positive on the active side. The active metal provides electrons directly to O2− then reduces one
molecule of O2− and one proton to be converted to form H2O2 (Figure 2). The amount of SOD-2
is different in each cell type, depending on the number of mitochondria. Specifically, the presence
of SOD-2 is essential for the survival of aerobic cells and the development of cellular resistance to
oxidative stress. SOD-3, an extracellular SOD (EC-SOD), also contains copper and zinc in its structure,
is synthesized inside the cell and secreted into the extracellular matrix [45]. SOD-3 enzyme is not
induced by its substrate or other oxidants and is regulated to coordinate with cytokines, rather than as
a response of individual cells to oxidants [46].
In neurodegenerative diseases, SOD-1 and SOD-2 genes appear to be disrupted and/or mutated.
SOD-1 gene mutations produce diverse cellular changes such as alteration of gene expression, unusual
protein interactions, caspase activation, mitochondrial dysfunction, and cytoskeletal abnormalities
in familial ALS [47]. Overexpression of SOD-1 protects neurons against the neurotoxic effects of
amyloid beta (Aβ), and loss of SOD-1 accelerates aging-related pathologies and reduces lifespan in
mice [48–50]. SOD-1 deficiency in an AD model showed that it was associated with augmented Aβ
oligomerization and memory impairment mediated by oxidative stress [51]. Overexpression of SOD-2
by treatment with sodium orthovanadate could rescue synaptic failure and neuronal cell death in the
hippocampus after kainic acid (KA)-induced oxidative stress; moreover, an increase in SOD-2 protected
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the neuronal death from oxidative injury [52]. Impaired SOD-2 is a common potential pathogenesis
related to oxidative stress in PD and AD [6]. In human amyloid precursor protein (hAPP) transgenic
mice with over 50% reduced SOD-2 activity, increased SOD-2 protects the age-related brain against
hAPP/Aβ-induced impairments [53]. Extracellularly administered SOD was effective in inhibiting
cell death and restoring healthy mitochondrial morphology in a monosodium glutamate-induced
excitotoxicity disease model [54]. An increase in SOD-2 can be expected to assist or improve neuronal
function and vascular pathology in AD as a therapeutic effect.
3.1.2. Catalase
Catalase (CAT), a heme-containing tetrameric protein is a common antioxidant enzyme naturally
produced by the body when exposed to oxygen. H2O2 generated inside the cell is enzymatically
catabolized in aerobic organisms by catalase and the activity of several peroxidases. CAT is one of the
most efficient enzymes that cannot be saturated by H2O2 at any concentration. It reacts with H2O2 to
form water/alcohol and oxygen using Fe as a cofactor [55,56]. CAT protects cells by detoxification of
the generated H2O2 and plays an important role in the acquisition of tolerance to oxidative stress as
an adaptive response [57]. CAT can maintain the concentration of O2 either for repeated rounds of
chemical reduction or for direct interaction with the toxin [58] (Figure 2). Furthermore, inhibition of
CAT activity results in enhanced cytotoxicity and increased ROS, indicating an important role of CAT in
maintaining the oxidative balance [59]. Specifically, mislocalized CAT is associated with accumulation
of H2O2 [60] and other ROS in the cells leading to compromised neurological function [61]. Thus,
deficiency or malfunction of CAT is postulated to be related to the pathogenesis of many age-associated
degenerative diseases.
CAT treatment reduces H2O2 levels and improves neuronal survival following Aβ-induced
toxicity in neuronal culture [62]. In Aβ toxicity, CAT–SKL (serine-lysine-leucine) treatment reduced
the pathology of microglial activation, and rat brains did not show long-term memory impairments via
the reduction of H2O2 levels [63]. In the PD model, mutant α-synuclein inhibited the expression and
activity of CAT and induced low catalase activity and high H2O2 production [64]. This antioxidant
enzyme plays an important role in maintaining oxidative balance.
3.1.3. Glutathione Peroxidase
Glutathione peroxidase (GPx) catalyzes the reduction of a variety of hydroperoxides (ROOH
and H2O2) to water or the corresponding alcohols using GSH to protect mammalian cells against
oxidative damage [65] (Figure 2). GPx has four identical subunits containing one selenocysteine in
each residue for essential enzyme activity, which are classified as selenium-containing GPxs (GPx1–4
and 6) and their non-selenium congeners (GPx5, 7, and 8) [30]. The glutathione redox cycle is mostly
active during low levels of oxidant stress, while CAT is more significant in protecting against severe
oxidant stress. GPx isoenzymes appear to have antioxidant functions at different locations and cellular
compartments, and the levels of expression of each isoform vary depending on the type of tissue,
even though their expression is omnipresent. Furthermore, GPx is responsible for the conversion of
GSH to oxidized glutathione disulfide (GSSG) and glutathione reductase (GR) reduces GSSG back to
GSH [66]. GPx1 and GPx4 are found in most tissues and the predominant forms of GPx are found
in brain tissue. GPx1 reduces H2O2 and organic hydroperoxides and is expressed both in neurons
and astrocytes [67]. GPx4, the phospholipid hydroperoxide glutathione peroxidase, is located in
the cytosol and a membrane fraction that can directly reduce phospholipid hydroperoxides, fatty
acid hydroperoxides, and cholesterol hydroperoxides [68]. In the brain, mitochondrial and cytosolic
GPx4 isoforms have been detected in neurons of the cerebral cortex, hippocampus, and cerebellum.
In contrast, GPx4 in glial cells is barely activated under normal physiological conditions, whereas
reactive astrocytes upregulate the expression of GPx4 following selective brain injury [31]. Recently,
GPx4 has become well known as a key regulatory factor in ferroptosis which is a non-apoptotic and
iron-dependent programmed cell death pathway that causes a rapid elevation of oxidative stress [69].
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As the function of GPx is related to normal development and cellular metabolism via the regulation of
oxidative stress, GPx4 function is potentially the key for cell survival.
GPx activity decreased significantly in PC12 cells during oxygen-glucose deprivation [70], and a
two-fold increase in GPx and a three-fold increase in CAT activities were observed during a time course
that reflected the temporal increase in nerve growth factor (NGF) in a brain contusion model [71].
The ferroptotic potential of neurons in the forebrain regions of the hippocampus and cerebral cortex is
severely affected in AD patients, with increased vulnerability to ferroptosis. The role of GPx4 as a key
regulator of ferroptosis was observed in Gpx4BIKO transgenic mice, a mouse model with a conditional
deletion of GPx4 in forebrain neurons. Gpx4BIKO transgenic mice showed significant deficits in spatial
learning and memory function and exhibited hippocampal neurodegeneration compared to control
mice [72]. In human PD tissue biopsies, GPx4 expression was upregulated and ferroptosis-related
events were observed [73].
3.1.4. Thioredoxin
The thioredoxin (Trx) system consists of two types of antioxidant oxidoreductase proteins, Trx and
thioredoxin reductase (TrxRs) with NADPH as an electron donor. Trx has a conserved active site such
as Cys-Pro-Gly-Cys, that has an important function of acting as an active oxidoreductase and electron
donor of some peroxiredoxins (Prx) which are crucial for the reduction of peroxides [74]. Trx is an
important regulator of cellular function that can respond to redox balance by modulating signaling
pathways, transcription factors, and immunological responses for cell survival in many conditions,
including neurodegenerative diseases [75]. There are three isoforms in the Trx family such as Trx1 in
the cytosol, Trx2 in the mitochondria, and a testis-specific Trx3 in mammalian cells. Trx1 exists in cell
compartments such as the nucleus and the plasma membrane or as a secreted protein, depending on
its localization and function in different cell types [76]. Trx1 is coupled with Prx 1/2 and methionine
sulfoxide reductase and is essential role in the control of growth and apoptosis. TrxR 1 and Trx 1 are
observed in neuronal synaptic vesicles. In addition, Trx 1 and 2 expressions are also present mainly in
rat brain neurons. Neurons with mitochondrial dysfunction by complex IV inhibition show low levels
of Trx and are thus, more vulnerable to H2O2. Reduced Trx is a powerful reductase that acts through a
disulfide–dithiol exchange mechanism to catalyze the conversion of disulfide bonds into thiols with
high efficiency [77]. The disulfides in the oxidized Trx are converted to thiols by the consumption
of NADPH [78] (Figure 2). TrxR, a homodimer, catalyzes the reduction of the disulfide at the Trx
active site and is encoded by three distinct genes: the cytosolic TrxR (TrxR1), mitochondrial TrxR
(TrxR2), and thioredoxin-glutaredoxin reductase (TrxR3). TrxR can directly reduce substrates such as
peroxides, including lipid hydroperoxides, H2O2, and protein disulfide isomerase [76,79]. TrxR is also
involved in the regeneration of other antioxidant molecules such as dehydroascorbate, lipoic acid,
and ubiquinone [80–82]. TrxR is very important when other selenoproteins including GPx lose most of
their activity and it effectively donates electrons during DNA synthesis [83]. TrxR activation in the rat
brain can be maintained at a certain level under severe selenium (Se)-deficient conditions. Both Trx
and TrxR are widely expressed in tissues and organs, including the brain. In a central nervous system
(CNS) study, it has been suggested that increased expression of Trx and TrxR is closely associated with
cell damage due to oxidative stress [84,85]. In addition, NADPH and human TrxR are efficient electron
donors to human plasma peroxidase and reduce hyperoxides, even with low GSH capacity [86].
The upregulation of Trx was observed as a neuroprotective effect on retinal ganglion cells against
oxidative stress-induced neurodegeneration [87]. Overexpression of Trx1 attenuated endoplasmic
reticulum stress by regulating the activation of the molecular mechanism for neuroprotection
in an in vitro and in vivo model of PD [88]. In AD brains, TrxR activity was increased in the
cerebellum and amygdala [89]. It has been implied that TrxR activation increases a compensatory
mechanism during increased oxidative stress that is limited by the substrate Trx and the subsequent
neurodegeneration seen in AD. Another evidence for the peripheral response to oxidative stress during
neurodegeneration is the reduction of Trx1 and TrxR1 in the plasma and erythrocytes in blood samples
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from patients with Huntington’s disease (HD) [90]. Exogenously administered human recombinant
Trx attenuates the generation of ROS involved in cytotoxic mechanisms, ameliorates neuronal damage,
and augments neurogenesis following brain ischemia/reperfusion injury in rats [91]. In the ischemic
brain, administration of Prx3 and Trx2 shows substantial neuroprotective effects by reducing oxidative
stress [92].
Important enzymatic antioxidants such as SOD, CAT, GPx, and Trx remove superoxide
and peroxides before they react with metal catalysts to form more reactive species (Figure 2).
Peroxidative chain reactions initiated by reactive species that escape enzymatic degradation are
terminated via chain-breaking antioxidants, including water-soluble ascorbate, lipid-soluble vitamin E,
and ubiquinone. To enhance the antioxidative effect, oxidative stress should be controlled by supplying
all the antioxidant nutrients and by minimizing the effect of substances that stimulate reactive oxygen
metabolites (ROM) [93].
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Figure 2. Enzy atic antioxidant defense syste against the production of reactive oxygen species
(R S). Various pathways of cell death caused by ROS and its transformation are observed in brain injury.
NADPH oxidase and mitochondrial respiratory transport chain are known as major cellular sources of
the superoxide radical anion (O2−). The superoxide radical anion reacts with nitric oxide (NO) to form
the per xynitrite anion (ONOO−) which mediates oxidative modification of protein residues via a
interaction with NO. The superoxide radical is dismuted by the superoxi e dismutase enzyme (SOD) to
form hydrogen per xide. In addition, manga ese containing sup roxide dismutase (Mn-SOD) reduces
the superoxide radical anion generate during the lectron transport chain in the mitochondrial matrix.
Ca alase (CAT) and/or glutathione peroxidase (GPx) decomp ses hydrogen p r xide to water and
oxygen by enzymatic reactions. Hydrogen peroxide is decomp s d into reactive hydroxyl radicals
by reaction with catalytically active redox metals such as (copper and iron). Hydroxyl radicals can
react with oxygen to fo m peroxyl or alkoxyl radicals which can lead to lipid peroxidation and react
with DNA and primarily cause damage to DNA. Peroxiredoxins (Prx) and thioredoxin (Trx) act as
redox-regulated pro eins to additional redox relay b ses.
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3.2. Non-Enzymatic Antioxidants
3.2.1. Antioxidant Enzyme Cofactors (Selenium, Coenzyme Q10, Zinc)
Selenium
Selenium (Se) is an enzymatic cofactor and an essential component of selenoaminoacids and
selenoproteins. Se has numerous biological functions related to redox signaling, antioxidant defense
systems, thyroid hormone metabolism, and humoral and cell-mediated immune responses [94].
Se reacts with redox signals involving one- or two-electron transitions; however, it is less
reactive and prefers higher oxidation states. The biological activity of Se varies depending on
its concentration: normal growth and development at low concentrations, homeostatic function
at moderate concentrations, and induced toxicity at high concentrations [95]. The complex
biological functions of Se are found in general body proteins that mainly and effectively act through
25 selenoproteins that have selenocysteine at their active center in humans [96]. Over half of the
selenoproteins exhibit antioxidant activity, of which the GPx family and Trx reductase family are well
known. Selenoproteins constrain the activation of nuclear factor-κB (NF-κB) via redox signaling, which
prohibits a cytokine storm and the formation of reactive oxygen and nitrogen species. Se is essential for
brain function, but the Se expression level in the brain is rather poor compared to other tissues [97,98].
The distribution of Se in the human brain enriched in gray matter tended to be higher, while the white
matter was found to have reduced Se levels. Specifically, Se level was observed to be highest in the
hippocampus, cerebellum, and brainstem in the rat brain [99]. The mechanism of Se neuroprotection is
attributed to modulation of Ca2+ influx via ion channels, anti-inflammatory effect by abrogation of
microglia invasion, and biosynthesis stimulation of antioxidative selenoproteins in the brain [100,101].
Se is essential for the brain and plays an important role in the pathology of neuronal disorders
such as AD, PD, ALS, and epilepsy [96]. In Se-deficient transgenic mice, Aβ plaques showed more
than a two-fold increase compared to Se-adequate ones [102]. Selenite administration in a rat AD
model also showed attenuation of cognitive deficits, oxidative damage and morphological changes
in the hippocampus and cerebral cortex [103]. In a paraquat induced PD model, bradykinesia and
DNA damage reduction were observed by supplementing Se with selenite in drinking water [104].
Alterations of Se homeostasis in the HD model have been observed and a beneficial effect of selenite
supplementation in mice expressing mutant huntingtin has been reported. Additionally, autopsy of
the human HD and mouse HD brain showed decreased Se content [105]. Selenite administration
prevents secondary pathological events, thus, contributing to the reduction of apoptotic cell death and
prevention of neuronal destruction in the cortex and hippocampus of traumatic brain injury [106,107]
Coenzyme Q
Coenzyme Q (CoQ) is a remarkable liposoluble ubiquinone with a long isoprenoid side chain and
a main component of the internal mitochondria membrane, Golgi complex membrane, and lysosomal
membrane. CoQ is an endogenous free radical scavenger and enzyme cofactor produced by most
human cells and is abundant in the brain and intestine in mitochondria, the site of oxidative
phosphorylation [108]. It is biosynthesized by all membranes and a component of the mitochondrial
respiratory chain, which participates in electron transport [109]. CoQ in either reduced form,
hydroquinone or ubiquinol, is a potent lipophilic antioxidant and is also involved in the regeneration
and recycling of other antioxidants such as tocopherol and ascorbate [110]. CoQ is an important
antioxidant that protects cellular membranes and lipoproteins against the toxic effects of free radicals
that are generated during general metabolism [111]. The redox functions of CoQ mainly occur in the
mitochondria as electrons shuttle between complexes I and II of the respiratory chain. Dehydrogenases
oxidize NADH, NADPH, and dihydroflavine-adenine dinucleotide (FADH2) and transfer protons
and electrons to ubiquinone, which is converted to ubiquinol. Finally, the protons transfer to the
mitochondrial matrix and the electrons move to the cytochromes. Thus, cytochromes reduce the
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superoxide radical anion to water with electrons and protons from the matrix. These processes are
required to produce ATP [108]. TrxRs within the cytosol induce the reduction of CoQ to ubiquinol
and maintain the extra-mitochondrial antioxidant defense [112]. CoQ is synthesized by at least
12 proteins that form a multiprotein complex in the mitochondria, and the pathogenesis of CoQ10
deficiency involves deficient ATP production and excessive ROS formation in humans. However,
CoQ10 deficiency is unique among mitochondrial disorders because an effective treatment is available
by oral CoQ10 supplementation, to which many patients respond well [113,114]. However, dietary
supplementation is still challenging due to the low bioavailability of the compound. Because CoQ10
levels decline with age, it has been studied in a variety of neurodegenerative disorders and aging but
with disparate results [115].
In KA-induced oxidative injury in vitro [116], an increased number of surviving CA3 neurons
was observed at 0.1 and 1 µM concentrations in CoQ10-treated groups using cresyl violet staining.
CoQ10 (0.01, 0.1, and 1 µM) treatment significantly decreased 2,7-dichlorofluorescein fluorescence,
and the expression of NQO1 in the CoQ10-treated groups was significantly lower than that in controls,
indicating the protective role of CoQ10 in hippocampal neurons against oxidative stress. Rats exposed
to intrastriatal CoQ10 showed a larger number of dopaminergic neurons, higher expression of
neurogenetic and angiogenetic factors, and less inflammation, and these effects were more prominent
than the orally administered CoQ10. Thus, continuous intrastriatal administration of low doses of
CoQ10 showed a more effective strategy to prevent dopaminergic neuronal degeneration in a PD rat
model induced by 6-hydroxydopamine [117]. In patients with acute ischemic stroke, a significant
increase in CoQ10 level was observed with the administration of CoQ10 (300 mg/day group) compared
with the placebo group. CoQ10 supplementation attenuated oxidative stress and neuroinflammatory
marker levels and improved the neurological outcome scale and antioxidant enzyme activity [118].
In PD patients, the total Unified Parkinson’s Disease Rating Scale (UPDRS) scores decreased in
the CoQ10-treated group, indicating amelioration of the symptoms and significant improvement in
wearing-off in PD [119]. CoQ10 increased a reduced glutathione and SOD levels in patients with
pregabalin-treated fibromyalgia. The supplementation of CoQ10 effectively reduced pain sensation,
anxiety and brain activity, mitochondrial oxidative stress, and inflammation [120].
Zinc and Essential Metals
Zinc, a redox inactive metal, does not directly interact with ROS but has a crucial role in
maintaining redox balance for the antioxidant defense system in various ways in the cell. Zinc increases
the activation of antioxidant enzymes such as SOD, GPx, and CAT. It also acts as a direct cofactor
of SOD-1 and SOD-3 and as an indirect cofactor for GPx [121]. Zinc inhibits important pro-oxidant
enzymes such as NADPH oxidase, inducible nitric oxide synthetase (iNOS), and the reduced form of
nicotinamide adenine dinucleotide (NMDA) and regulates oxidant production and metal-induced
oxidative damage. Zinc is dynamically associated with sulfur in protein cysteine clusters. It mediates
the induction of the zinc-binding protein metallothionein which releases the metal under oxidative
conditions and acts as an Se scavenging oxidant. Zinc is involved in the regulation of glutathione
metabolism and the overall protein thiol redox status [122]. Zinc competes with redox-active transition
metals, iron and copper, for certain binding sites. When zinc binds to these sites, copper and iron
are forced to undergo hydrolytic polymerization into unreactive structures, thereby prohibiting the
catalysis of free radical formation and the initiation of lipid peroxidation [121–123]. Zinc is mainly
expressed in the hippocampus, amygdala, cerebral cortex, thalamus, and olfactory cortex in the
brain [124] and is stored as free zinc ions (Zn2+) in the presynaptic glutamatergic neurons. Zinc in
synaptic vesicles is released with glutamate and acts as a potent extracellular modulator by interacting
with many synaptic receptors during synaptic activity [123].
Co-treatment with zinc and Se significantly decreased mitochondrial dysfunction, ROS levels,
and lipid peroxidation levels, while significantly increasing cognitive performance, SOD, glutathione
peroxidase, and catalase activity in the mitochondria of the brain in an AD rat model [125]. In a
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double-blind, placebo-controlled trial of zinc supplementation for premenstrual syndrome, sixty women
(18–30 years) were randomly assigned to receive either 30 mg of zinc gluconate and/or placebo for 12 weeks.
The zinc-administered group showed beneficial effects on physical and psychological symptoms of
premenstrual syndrome, total antioxidant capacity, and brain-derived neurotrophic factor [126].
Other essential metals, such as copper, iron, and magnesium, play an important role in the
maintenance of cell homeostasis and preservation of life. They display important structural, regulatory,
and catalytic functions in different types of proteins, such as enzymes, receptors, and transporters.
Cu+ and magnesium are the cofactors for enzymes such as COX and/or supper zinc, SOD, and neuronal
Cu enrichment predispose to Cu2+-catalyzed Fenton chemistry and H2O2-assisted protein oxidation.
In particularly, iron continuously shifts between ferrous ion (Fe2+) and ferric ion (Fe3+) states in a
redox reaction in the presence of O2. The constitution of iron in the body is in the form of 65% (Fe2+)
ions bound to hemoglobin; less than 10% of ions are expressed with myoglobin (Fe2+), cytochromes
(Fe2+ or Fe3+), and iron-containing enzymes, and 25% of the ions are bound to iron-storage proteins
such as transferrin, ferritin, and hemosiderin [127]. Iron present in the cells in the reduced (Fe2+) and
oxidized (Fe3+) states can serve both as an electron donor and electron acceptor. Particularly, the
ferrous form of iron can act as a catalyst in the potentiation of oxygen toxicity by generating a wide
range of free radical species, including hydroxyl radicals. In addition, an excessive amount of this
essential metal induces toxicity, leading to pathological conditions generated by oxidative stress and
neurodegeneration [128]. Although homeostasis of iron is essential for physiological functions in the
brain, less than 2% of total body iron is present in the brain. Iron contributes to the activity of various
enzymes involved in neurotransmitter synthesis and myelination of axons of motor neurons in the
brain. Iron accumulation induces features of neurodegenerative disorders including AD, PD, HD, ALS,
and neurodegeneration with brain iron accumulation (NBIA). The pathogenesis of neurodegenerative
diseases shows a relationship with a dramatic increase in iron content in the brain, which is correlated
with the production of ROS [127].
3.2.2. ROS/RNS Scavengers (Vitamin C, E, and A)
Vitamin C
Ascorbate (ascorbic acid, AA), a ubiquitous water-soluble antioxidant and a cofactor for several
enzymes, can inhibit the generation of ROS, directly scavenge ROS/RNS, and repair other oxidized
scavengers [129]. ROS generation is limited by ascorbate through the inhibition of NOX and nNOS.
It also helps in the regeneration of alpha-tocopherol from alpha-tocopheroxyl radical and repair of
glutathione. The highest concentration of ascorbate is expressed in the brain and is involved in
CNS homeostasis. Endogenous ascorbate exists in two biological forms, the deprotonated ascorbate
anion and dehydroascorbate (DHA), which is the product of the two-electron reversible oxidation of
ascorbate [129]. The mechanism of ascorbate uptake involves absorption of dietary ascorbate in the
intestine by sodium-dependent transporter-1 (SVCT-1) and dissolution in the blood. Ascorbate enters
the CNS by slow transport from the plasma to the cerebrospinal fluid across the choroid plexus
epithelium. Ascorbate can easily enter the brain through the glucose transporter (GLUT1) when a
considerable amount of DHA is present in the blood. Ascorbate or DHA in the cerebrospinal fluid enters
the neuron via sodium-dependent transporter-2 (SVCT-2) or GLUT1 transporters [130,131]. Once they
enter the neuron, DHA can be reduced to ascorbate or released by GLUT1. Ascorbate produces
ascorbate free radicals as one electron donor, which is reduced back to ascorbate within the cells
by NADH- and NADPH-dependent reductase. Glial cells obtain ascorbate by reduction of DHA
through GLUT1, and ascorbate uptake does not involve SVCT-2, which is different from neurons [131].
DHA goes through GLUT1 slowly to enter the choroid plexus and astrocytes [132–134]. The rapid
entry of ascorbate is driven by SVCT-2 through the blood-brain-barrier (BBB) to neurons, and ascorbate
modulates SVCT-2 translocation to the plasma membrane, ensuring optimal ascorbate uptake in
the neurons [135,136] (Figure 3). The oxidizing and free radical scavenging activity of ascorbate
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inside the cell is not limited to the aqueous phase, but also includes protection of membranes and
other hydrophobic compartments through interaction with vitamin E [137]. Aging decreases the
extracellular concentration and the uptake of ascorbate in the brain, which is consistent with an increase
in oxidative stress. The neurobiological role of ascorbate in the brain is seen in neuromodulation and
neuroprotection [129]. In the role of a neuromodulator, ascorbate release is involved in the uptake
or clearance of glutamate from the synapse after its release from the axon terminals. Specifically,
L-glutamate promotes ascorbate release as a consequence of removing glutamate from the synapse [138].
Although ascorbate does not act as a classical neurotransmitter, extracellular ascorbate may influence
neurotransmission. In particular, ascorbate directly modulates neural excitability through inhibition of
T-type Ca2+ channels [139], participates in the reduction of extracellular oxidants, which effects the
redox status of catecholamines [140], and influences the release of biogenic amines in striatum [141]
and pituitary neuropeptides [142]. Another neuroprotective role of ascorbate is the attenuation of
neurotoxicity, which results from the scavenging activity [143]. Ascorbate inhibits the oxidative stress
triggered by various neurotoxins and protects against ethanol-induced apoptotic neurodegeneration in
prenatal rat hippocampal neurons [144]. Oxidative stress in stroke, hypoxia, ischemia, and seizure
activity leads to massive glutamate release and subsequent excitotoxicity, a result of over-activation of
glutamate receptors [145]. Therefore, ascorbate can protect against glutamate-induced excitotoxicity
and neurodegeneration.
Many researchers have reported that neurodegeneration can be reversed or lessened by ascorbate
treatment [146–148]. From the viewpoint of the effect of aging, the extracellular concentration and
uptake of ascorbate is decreased in the brain, which is consistent with an increase in oxidative
stress [149]. Moreover, excess ascorbate intake or deficiency may influence brain aging [150]. Thus,
careful maintenance of ascorbate levels in the brain may be important during the life span. There have
been extensive reviews on the role of ascorbate in the brain with a focus on neurodegenerative
disease [130,131]. Even though ascorbate has a complicated interaction with the neurotransmitter
system, ascorbate is considered relevant for use as an antioxidant therapy because neurons are sensitive
to ascorbate deficiency and excess oxidant stress. In our previous work [151], we studied the protective
effects of AA and DHA on KA-induced oxidative stress using organotypic hippocampal slice cultures.
After 12 h of KA treatment, significant delayed neuronal death was detected in the CA3, but not in
the CA1 region. Pretreatment with intermediate doses of AA and DHA significantly prevented cell
death and reduced ROS levels, as well as mitochondrial dysfunction in the CA3 region. However,
pretreatment with high doses of AA or DHA was not effective. Attempting to elevate the brain
ascorbate by the systemic administration of high doses of ascorbate is very difficult. The level of AA
in the extracellular fluid of the striatum was decreased in a transgenic mouse model of HD; hence,
restoring striatal extracellular AA levels with high doses of ascorbate improved behavior [152,153].
Vitamin E
Vitamin E is a major group of lipid-soluble antioxidants called tocopherols and tocotrienols, of
which the most biologically active isoform is α-tocopherol [154]. It is a major chain-breaking antioxidant
and exists in a low molar ratio compared to unsaturated phospholipids. The most important function
of vitamin E is its antioxidant activity, which protects the integrity of cellular membranes from
polyunsaturated fatty acid-generated oxygen free radicals and to act as a direct scavenger of superoxide
and hydroxyl radicals [154,155]. Based on studies of brain capillary endothelial cells, the mechanism
of entry of α-tocopherol into the CNS correlated to α-tocopherol and scavenger receptor class B type 1
(SRB1) levels. α-Tocopherol uptake occurs via a selective high-density lipoprotein (HDL) pathway,
which modulates the expression of SRB1 receptor [156–158]. Once α-tocopherol passes through the
BBB, it may be directly delivered to specialized astrocytes. Astrocyte-synthesized apolipoprotein E
(ApoE) moves through the cerebral spinal fluid transporting α-tocopherol between various cell types
in the CNS cell [154,159]. ApoE lipoprotein particles in astrocytes are secreted through membrane
proteins and interact with low-density lipoprotein receptor-related protein (LRP) on the neurons [160].
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The neurons take up these ApoE particles and distribute them throughout the body, axon, and dendrites
to preserve the membrane from lipid peroxidation (Figure 3). The expression of α-tocopherol transfer
protein is enhanced by an increase in ROS, and it is useful for combating neuronal damage.
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Figure 3. Schematic representation of vitamin uptake and protective mechanisms by exogenous
vitamins as antioxidants. Vitamin C: During uptake in the CNS, ascorbate passes through the BBB to
enter directly through the SVCT-2 and/or possibly DHA through GLUT1s. Moreover, the neuronal
uptake of as orbate ccurs through SVCT-2 and DHA via th GLUT1s In the neuron, DHA can be
reduced to ascorbate or released back into the extracellular space by GLUT1. Ascorbate free radicals
convert to form DHA and ascorbate. Ascorbate recycles both the ascorbate free radical and DHA by
cellular metabolism. Astrocytes contain ascorbate from recycling of DHA which is taken up through
GLUT1s. Neurons directly acquire scorbate via SVCT-2. Vitamin E: With respect to vitami E uptake,
HDL particles can pass through SRB1 receptors ex ressed on endothelial cell . Astrocytes that exist
adjacent to the BBB take up vitamin E into the inner cell membrane. Synthesized ApoE lipoproteins take
up vitamin E that is left out of an ABC transporter, for transport into neurons through LRP1 requiring
vitamin E for maintenance or during conditions of oxidative stress. Vitamin A: In cellular retinoid
signaling pathways, retinol is etabolized to ll-trans-retinoic acid (ATRA). Vitamin A (r tinol, ROL)
binds to plasma retinol binding prot in (RBP4) and circulates; RBP4 protein binds to the membrane
receptor STAR6 to promote cellular absorption of retinol from the cells. A chylomicron remnant (CMRE),
as a form of circulating vitamin A, can serve as a source of vitamin A for the cells and retinol is esterified
and stored by lecithin: retinol acyltransferase (LRAT) and is reversibly oxidized to retinaldehyde (RAL)
by retinol dehydrogenase (RDH/ADH). In addition, retinol is further oxidized to RA in an irreversible
manner by retinaldehyde dehydrogenase (R LDH). ATRA regulates gene transcripti n through retinoic
acid receptors (RAR) and/or retinoid X receptors (RXRs) which are bound to retinoic acid response
elements (RARE) in the nucleus. These representative schematics are modified from [130,154,161].
Abbreviations: VC, vitamin C; VE, vitamin E; VA, vitamin A; ASC, ascorbate; ASF, ascorbate free radical;
DHA, dehydroascorbic acid; GLUT1, glucose transports; SVTC-2, sodium-dependent transporters;
LRP, lipoprotein receptor-related protein; GSH, glutathione; ApoE, apolipoprotein E; HDL, density
lipoprotein; CMRE, chylomicron remnant; CRABP, cellular retinoic acid-binding protein; LRAT,
lethicin: retinol acyltransferase; RBP, retinol binding protein; RAL, retinaldehyde; RDH/ADH, retinol
dehydrogenase; RALDH, retinaldehyde dehydrogenase; RXR, retinoid X receptors; RAR, retinoic acid
receptors; ATRA, all-trans-retinoic acid; BBB, blood–brain barrier.
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The antioxidant ability of vitamin E is continuously restored via vitamin E recycling by other
antioxidants such as vitamin C, ubiquinols, and thiols. The half-life of vitamin E in the brain
tissue is slower than that of other vitamins, and it is also actively retained and protected from
auto-oxidation in the brain [162]. The distribution of α-tocopherol is significantly different in the
brain. These CNS-regional disparities are suggestive of the specific protective antioxidant effect of
α-tocopherol. Specifically, the concentrations of α-tocopherol were relatively higher in the nuclear
membranes than in the other membranes of the brain. It has been suggested thatα-tocopherol may play a
role in nuclear-associated functions in the cerebellum and striatum, wherein preferential accumulation
of α-tocopherol in the membrane was most apparent [163]. Vitamin E, similar to other radical
scavengers/trappers, influences the flux of lipid hydroperoxide (LOOH), which is derived from both
spontaneous and enzymatic formation of lipid peroxyl radicals (LOO•) on the cellular membrane [164].
The effects of vitamin E on peroxidation activity appear to involve both the radical scavenging
mechanism such as the H atom donor activity and a physical interaction with the polyunsaturated
lipid substrate. Tocotrienols, another form of vitamin E that are highly metabolized, show more potent
inhibition of the phospholipase A2/lipoxygenases pathway as compared to tocopherols, and have
different cellular bioavailability, distribution, and protein interaction in the saturated and unsaturated
form of vitamin E in the brain [165]. Deficiency of vitamin E showed increased biochemical and
histological markers of oxidative stress, including total glutathione and lipid peroxidation in the CNS.
Therapeutic effects of α-tocopherol by application of vitamin E in neurological lesions caused by
neuronal excitotoxicity and the conditional activation of neuroglial cells have also been reported. In KA
treatment-induced oxidative stress [166], delayed neuronal death was detected in the hippocampal
CA3 region and ROS formation and lipid peroxidation were also increased. Both co-treatment and
post-treatment withα-tocopherol (100µM) orα-tocotrienol (100µM) significantly increased cell survival
and reduced the number of TUNEL-positive cells in the CA3 region. Increased dichlorofluorescein
(DCF) fluorescence and thiobarbiturate reactive substance (TBARS) levels were decreased by drug
treatment (Figure 4). In AD patients, long-term administration of vitamin D and E alone or in
combination could inhibit morphological changes of neurons and improve learning and memory [167].
Vitamin E prevented the memory impairment associated with post-traumatic stress disorder (PTSD)-like
behavior in rats. Significant decreases in oxidative stress biomarkers were detected with reduced
glutathione/oxidized glutathione (GSH/GSSG) ratio [168]. In PD patients, omega-3 fatty acid and
vitamin E co-supplementation had favorable effects on the UPDRS score and increased the total
antioxidant capacity (TAC) and GSH concentration compared to placebo [169].
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faster than α-tocopherol, implying that β-carotene is more favorable than α-tocopherol to quench
lipophilic radicals in the membrane. The most efficient synergistic inhibition during oxidative stress
was observed with a combination treatment of α-tocopherol and ascorbic acid [179].
Retinoids, compounds structurally related to vitamin A, are considered vitamin A derivatives
that contribute to regular cellular morphogenesis, proliferation, and differentiation. Retinoids are
involved in normal signaling cascades in modulating brain functions [180]. Retinoids modulate the
availability of glucocorticosteroids in the brain, an important biological mechanism that can be explored
in many stress-related pathologies to prevent alterations in the plasticity of the hippocampus [181].
Retinol metabolic pathways have shown that retinol can be stored intracellularly as retinyl esters
and metabolized into all-trans-retinoic acid (ATRA) as a bioactive derivative. ATRA induces cellular
differentiation and growth by reacting to retinoic acid receptors (RARs). Cellular retinol-binding
proteins (CRBP-I and II) and cellular retinoic acid-binding proteins (CRABP-I, II) are distributed in the
adult CNS. Furthermore, CRBP-I distribution parallels that of ATRA with expression in the meninges,
hippocampus, amygdala, and olfactory bulb [182] (Figure 3). Under oxidative stress conditions such
as metal exposure and production and accumulation of ROS, retinoids protect the cells against this
imbalance through multiple mechanisms, including interference with ROS production, scavenging free
radicals directly, upregulation of antioxidant enzymes, and signaling pathways involved in defense
system such as Nrf2 signaling [183]. It has also been observed that retinoic acid has a protective
effect on neuronal apoptosis and oxidative damage by reducing glutathione [184] and restoring
SOD-1 and SOD-2 in the hippocampal cells [185]. The role of retinoid signal transduction in the
control of dopaminergic neurotransmission was observed in the presence of high levels of retinoic
acid-synthesizing enzymes [186] and RAR, which may play a critical role in controlling the survival,
adaptation, and homeostatic regulation of the dopaminergic system [187]. Retinoid signaling play a
physiological role in synaptic plasticity and learning and memory behaviors [188].
Retinoic acid supplementation upregulated µ-type opioid receptor 1 (MOR1) and its signaling
and alleviated dyskinetic movements, which is a known consequence of prolonged administration
of L-DOPA, in Pitx3ak/ak mice [189]. Moreover, RA triggered the neuroprotective effect on DA
neurons in MPTP-treated mice model of PD. Administration of RA-loaded polymeric nanoparticle
significantly reduced the loss of DA neuron in the substantia nigra as well as their neuronal
fiber/axonal innervations in the striatum [190]. Moreover, oral administration of lycopene (5–20 mg/kg),
a carotenoid with unique pharmacological properties, attenuated oxidative stress in mice with PD,
which was induced with intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). Lycopene supplementation also inhibits apoptosis in PD mice by decreasing Bax and caspases,
and contrarily increasing Bcl-2 [191]. Dietary supplementation with astaxanthin, another carotenoid
family member, significantly decreased intracellular ROS accumulation in a hippocampal neuronal
cell line after exposure to glutamate and induced antioxidant mediators, such as heme oxygenase-1
(HO-1) and nuclear Nrf2 expression in vitro [192]. In multiple sclerosis (MS) patients, vitamin A
supplementation had a significant effect in the treatment group for fatigue and depression. In addition,
when a synthetic retinoid was tested, it showed reduction in inflammation, Aβ burden, and tau
phosphorylation with associated cognitive benefits in AD patients [193,194].
Aside from elucidating the efficiency of endogenous antioxidants, several studies have increasingly
accredited the role of various exogenous antioxidants. Limited clinical studies are reported herein and
are illustrated in Table 1. Table 1 also shows several examples of previously mentioned exogenous
antioxidant reactions that have worked in clinical settings. Although the administration of exogenous
antioxidants showed positive effects, there are some inconsistencies in clinical trials. The clinical
trials performed multivariable analyses with various factors, such as sample size, replication or
validation studies using the same agent and outcome measures, assessment of vitamins, different
conditions of endogenous antioxidants, long-term monitoring, etc., which caused variability because
of inconsistencies. In general, several common antioxidants and their clinical effects are described in
Table 1.
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Table 1. Clinical trials of antioxidant in neurodegenerative diseases.
Antioxidant Number ofPatients
Follow up
Period Dosage Route Effects Disease Reference
CoQ10 609 60 month 2400 mg/day Oral No Huntington [119,195]
40 96 week 300 mg/day Oral Y Parkinson
Selenium
7540 7 year 200 µg/day Oral No Alzheimer [107,196]
6 month 1000 µg/day I.V. Y Traumatic brain injury
Zinc 43 12 week 20 mg/day Oral Y Depression withmultiple sclerosis [197]
Vitamin A
50 28 day 30 mg/day Oral Y Alzheimer [191,198]
101 6 month 25,000 UI/day Oral Y Multiple sclerosis
Vitamin C
12 6 day 2 g/day Oral Y Hyperoxia [147,199]
60 3 month 500 mg/day Oral Y Trauma surgery
Vitamin E
7540 7 year 400 UI/day Oral No Alzheimer
[168,196,200]60 3 month 400 UI/day Oral Y Parkinson
50 12 month 45 UI/day Oral Y Parkinson
3.2.3. Nrf2 Antioxidant System
The transcription factor Nrf2 is characterized as a regulator of redox homeostasis and antioxidant
defense mechanisms. This protective pathway also encompasses the activation of a detoxification
network such as oxidation/reduction factors (Phase I), metabolizing enzymes (Phase II), efflux
transporters (Phase III), and free radical scavengers [201]. Oxidation/reduction factors consisting
of nearly 500 genes encoding proteins, including redox balancing factors, stress response proteins,
detoxifying enzymes, and metabolic enzymes such as NAD(P)H quinone oxidoreductase (NQO1),
HO-1, SOD, GST, GSR, GSH-Px, carbonyl reductase (CR), and glutamate-cysteine ligase (GCL) play
important roles in antioxidant and pro-survival effects and detoxification of xenobiotics. Nrf2 is
generally targeted for ubiquitin-mediated degradation by its endogenous inhibitor Keap1, but oxidative
modification of Keap1 inhibits the Nrf2 degradation process during conditions of redox imbalance [202].
To maintain cellular redox homeostasis, basal Nrf2 accumulation increases to mediate the normal
expression of antioxidant response element (ARE)-dependent genes in the nucleus. The mitochondrial
membrane directly interacts with Nrf2 which can respond to mitochondrial oxidative stressors that
can collapse cellular bioenergetics leading to cell apoptosis [203]. Thus, the Keap1/Nrf2 system is
another good homeostatic regulator of intrinsic cellular antioxidant defense and mitochondrial health.
The suppression of Nrf2 activity increases the susceptibility of the brain to the damaging effects of
oxidative stress and inflammatory stimuli [204]. Nrf2 activation promotes neuroprotective effects in both
in vitro and in vivo neurodegenerative models. Nrf2 activity diminishes with age, and consequently,
the effect of antioxidant enzyme activity decreases. Nrf2/ARE system impairment leads to higher
susceptibility to oxidative injury, abnormal protein aggregation and neurodegeneration in the brain.
Many studies have demonstrated the importance of the Nrf2/ARE pathway in the pathogenesis and
control of neurological disorders, including PD, AD, ischemia, and other neurodegenerative diseases.
After middle cerebral artery occlusion (MCAO) in rats, Keap1 levels are decreased and this loss is
correlated with an increase in Nrf2 and its downstream proteins, such as thioredoxins, GSH synthases,
and HO-1 [205]. Stroke models of Nrf2-deficient mice exhibit higher levels of ROS than the wild-type
littermates, which supports the natural compensatory mechanism of Nrf2 [206]. In AD transgenic mice,
Nrf2-deficiency brains presented increased marker of oxidative stress and exhibited deficits in spatial
learning and memory [204]. Nrf2 knockout and wild-type mice can be administered MPTP with doses
ranging from 20 to 60 mg/kg for an animal model of PD. Nrf2−/− mice exhibited increased sensitivity to
the dopaminergic toxins MPTP and 6-OHDA [207]. Nrf2 deficiency increased the MPTP sensitivity by
30 mg/kg administration of MPTP, but astrocytic Nrf2 overexpression showed the amelioration of MPTP
toxicity in ARE-hPAP mice [208]. Astrocytic Nrf2 reduced the MPTP neurotoxicity by β-lapachone
treatment in PD models [209].
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4. Conclusions
Brains are metabolically active and have a high demand for large amounts of ATP to maintain
their physiological function. Additionally, the brain has a relatively low level of antioxidants, low
repair capacity, non-replicating nature of neuronal cells, and a high ratio of membrane surface to
cytoplasm. ROS production is largely through oxidative phosphorylation and increased free radicals
play a central role in neurological disorders by the imbalance of pro-oxidant and antioxidant agents
in the brain. This underpins the importance of targeting antioxidant systems to counteract the
oxidative stress and associated brain diseases. Indeed, the antioxidant system is important for the
rescue of neuronal cells from oxidative stress and preservation of the right redox balance in the
brain tissue by promoting antioxidative defenses for neutralizing ROS and by blocking transcription.
Currently, there is growing research interest in the development of new/combination exogenous
supplementation of antioxidants, retention of the functional integrity of intrinsic antioxidant systems
for preventing harmful CNS disorders, and identification of novel approaches to therapy to prevent
and/or reduce brain injury. Thus, high levels and variable metabolites in the brain indicate an
increased requirement for antioxidant defense systems as enzymatic and non-enzymatic molecules.
Redox biology fulfills important physiological functions that extend beyond its role on oxidative
stress, such as cell signaling [210,211]. Perhaps, ROS generation may be necessary for cell function.
Although their role is still ill-defined, the antioxidant systems may contribute to the controlled release
of ROS for normal brain function.
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